CD4 and myeloid sarcoma: We utilized ATAC-seq data performed in flow-sorted bulk CD4 T and B cell subsets (n = 6) derived from six patients with MS who were not treated with immunomodulatory therapy within at least 4 months of sample collection (see Additional file 1, Table S13 for clinical details).